The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN StudyMichele Del Vecchio, Paola Queirolo, Dario Palleschi et al.|Cancers|2023Cited by 2
Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).Roberta Rudà, Riccardo Soffietti, Giuseppe Lombardi et al.|Journal of Clinical Oncology|2016Cited by 0
2900 Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)Giuseppe Lombardi, Roberta Rudà, Silvia Scoccianti et al.|European Journal of Cancer|2015Cited by 0
Prognostic factors in glioblastoma patients treated with the nitrosourea fotemustine at first relapse after the Stupp regimen: results from the GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)Matteo Santoni, Roberta Rudà, Giuseppe Lombardi et al.|Annals of Oncology|2015Cited by 0
GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.Roberta Rudà, Riccardo Soffietti, Giuseppe Lombardi et al.|Journal of Clinical Oncology|2015Cited by 0